Ovarian Cancer

Orphan Drug Status Awarded for O-Vax Vaccine

Published in Women's Health Weekly, October 26th, 2000

Avax Technologies, Inc. (AVXT), Kansas City, Missouri, announced that its investigational, proprietary Autologous Cell Vaccine technology (AC Vaccine) for the treatment of ovarian cancer as an adjuvant therapy, O-Vax, received Orphan Drug designation from the U.S. Food and Drug Administration (FDA).

Orphan drug designation for O-Vax entitles AVAX to exclusive marketing rights in the United States on that vaccine for seven years following marketing approval, and enables the company to obtain research funding, tax credits for certain research expenses, and a waiver from the application user fee.

AVAX is conducting a Phase II multicenter clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-10-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry